New and emerging antiresorptive treatments in osteoporosis

Current Drug Safety

Volumn 6, Issue 2, 2011, Pages 75-88

  Rejnmark, Lars ^a   Mosekilde, Leif ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Antiresorptives; Catepsin K inhibitor; Denosumab; Fracture; Osteoporosis treatment

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ARZOXIFENE; BALICATIB; BAZEDOXIFENE; CARBOXY TERMINAL TELOPEPTIDE; CENTCHROMAN; CHLORIDE CHANNEL; DENOSUMAB; GLUCAGON LIKE PEPTIDE 2; IDOXIFENE; LASOFOXIFENE; ODANACATIB; PARATHYROID HORMONE; RALOXIFENE; SARACATINIB; VITRONECTIN;

ARTHRALGIA; BACKACHE; BONE DEMINERALIZATION; BONE METASTASIS; BRAIN VENTRICLE; CATARACT; CELLULITIS; CONSTIPATION; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GENE MUTATION; HISTOLOGY; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPERTROPHY; HYPOCALCEMIA; LEG CRAMP; LOW DRUG DOSE; LUNG EMBOLISM; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYP; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SORE THROAT; STROKE; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VENOUS THROMBOEMBOLISM;

EID: 79958185787     PISSN: 15748863     EISSN: 15748863     Source Type: Journal    
DOI: 10.2174/157488611795684686     Document Type: Review

References (122)

1. Thomsen JS, Ebbesen EN, Mosekilde L. Age-related differences between thinning of horizontal and vertical trabeculae in human lumbar bone as assessed by a new computerized method. Bone 2002; 31: 136-142.
2. Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Advances in Therapy 2008; 25: 1235-1256.
3. Scheven BAA, Visser JWM, Nijweide PJ. In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 1986; 321: 79-81.
4. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000; 97: 1566-1571.
5. Fuller K, Owens JM, Jagger CJ, et al. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. The Journal of Experimental Medicine 1993; 178: 1733-1744.
6. Hodge JM, Kirkland MA, Nicholson GC. Multiple roles of M-CSF in human osteoclastogenesis. J Cell Biochem 2007; 102: 759-768.
7. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y. Acad Sci 2008; 1143: 123-150.
8. Lewiecki EM. Denosumab: an investigational drug for the management of postmenopausal osteoporosis. Biologics 2008; 2: 645-653.
9. Ueland T, Bollerslev J, Mosekilde L. Osteoklastfunktionen reguleres af naboosteoblaster. Ugeskrift for Laeger 2002; 164:3526-3530.
10. Simonet WS. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
11. Lacey DL. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
12. Lacey DL. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000; 157: 435-448.
13. Kingsley LA, Chirgwin JM, Guise TA. Breaking new ground to build bone. Proceedings of the National Academy of Sciences 2007; 104: 10753-10754.
14. Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 2008; 43: 813-818.
15. Turner AG, Tjahyono F, Chiu WS, et al. The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. Bone 2011; 48: 354-361.
16. Marie PJ. The calcium-sensing receptor in bone cells: A potential therapeutic target in osteoporosis. Bone 2010; 46: 571-577
17. Mentaverri R, Yano S, Chattopadhyay N, et al. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J 2006; 20: 2562-2564.
18. Okada Y, Morimoto I, Ura K, et al. Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. Endocr J 2002; 49: 483-495.
19. Anderson PH, Atkins GJ. The skeleton as an intracrine organ for vitamin D metabolism. Mol Aspects Med 2008; 29: 397-406.
20. Kogawa M, Findlay DM, Anderson PH, et al. Osteoclastic Metabolism of 25(OH)-Vitamin D3: A Potential Mechanism for Optimization of Bone Resorption. Endocrinology 2010; 151: 4613-4625.
21. Vaananen HK, Horton M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995; 108: 2729-2732.
22. Blair HC, Teitelbaum SL, Ghiselli R, et al. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989; 245: 855-857.
23. Henriksen K, Sørensen MG, Jensen VK, Dziegiel MH, Nosjean O, Karsdal MA. Ion Transporters Involved in Acidification of the Resorption Lacuna in Osteoclasts. Calcified Tissue International 2008; 83: 230-242.
24. Väänänen HK, Zhao H, Mulari M, et al. The cell biology of osteoclast function. J Cell Sci 2000; 113: 377-381.
25. Baron R, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 1985; 101: 2210-2222.
26. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18: 859-867.
27. Zuklys S, Balciunaite G, Agarwal A, et al. Normal Thymic Architecture and Negative Selection Are Associated with Aire Expression, the Gene Defective in the Autoimmune- Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED). J Immunol 2000; 165: 1976-1983.
28. Seibel MJ. The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clin Endocrinol (Oxf) 2008; 68: 839-849.
29. Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen HK. Removal of Osteoclast Bone Resorption Products by Transcytosis. Science 1997; 276: 270-273.
30. Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008; 99: 1237-1242.
31. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-2668.
32. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066.
33. Schwartzman J, Yazici Y. Denosumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med 2006; 354: 821-831.
34. Lewiecki EM, Miller PD, McClung MR. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007; 22: 1832-1841.
35. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153-161.
36. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25: 72-81.
37. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 2149-2157.
38. Genant HK, Engelke K, Hanley DA, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010; 47(1): 131-139.
39. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
40. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
41. Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182: 2670-2675.
42. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008; 43: 222-229.
43. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882.
44. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-1309.
45. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69: 872-875.
46. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. Endocrinology 1999; 140: 4382-4389.
47. Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 2009; 60: 1427-1437.
48. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440: 692-696.
49. Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in Osteoporosis and Oncology. Ann Pharmacother 2009; 43(9): 1445-1455.
50. Hofbauer LC, Schoppet M. Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases. JAMA 2004; 292(4): 490-495.
51. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62: 1619-1623.
52. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
53. Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010; 23: 440-446.
54. Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
55. Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010; 46: 1211-1222.
56. Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med 2009; 361: 818-820.
57. Kyrgidis A, Toulis K. Denosumab-related osteonecrosis of the jaws. Osteoporos Int 2011; 22: 369-370.
58. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010; 25: 2256-2265.
59. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267-2294.
60. Bühling F, Gerber A, Häckel C, et al. Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol 1999; 20: 612-619.
61. Lecaille F, Kaleta J, Brömme D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 2002; 102: 4459-4488.
62. Guo J, Bot I, de Nooijer R, et al. Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. Cardiovasc Res 2009; 81: 278-285.
63. Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 1996; 271: 12517-12524.
64. Fuller K, Lawrence KM, Ross JL, et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 2008; 42: 200-211.
65. Vääräniemi J, Halleen JM, Kaarlonen K, et al. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 2004; 19: 1432-1440.
66. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236-1238.
67. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009; 44: 199-207.
68. Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: Report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008; 59: 125-129.
69. Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011; 26(2): 242-251.
70. Robichaud J, Oballa R, Prasit P, et al. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J Med Chem 2003; 46: 3709-3727.
71. Littlewood-Evans A, Kokubo T, Ishibashi O, et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997; 20: 81-86.
72. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008; 18: 923-998.
73. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009; 86: 175-182.
74. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010; 25: 937-947.
75. Nishi Y, Atley L, Eyre DE, et al. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 1999; 14: 1902-1908.
76. Chappard D, Libouban H, Mindeholm L, Baslé MF, Legrand E, Audran M. The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients. Microsc Res Tech 2010; 73: 726-732.
77. Kiviranta R, Morko J, Alatalo SL, et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 2005; 36: 159-172.
78. Nakasato YR, Janckila AJ, Halleen JM, Vaananen HK, Walton SP, Yam LT. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 1999; 45: 2150-2157.
79. Fratzl-Zelman N, Valenta A, Roschger P, et al. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 2004; 89: 1538-1547.
80. Riggs BL, Khosla S, Melton LJ 3rd. Sex Steroids and the Construction and Conservation of the Adult Skeleton. Endocrine Reviews 2002; 23: 279-302.
81. Eghbali-Fatourechi G et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111: 1221-1230.
82. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130: 811-823.
83. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
84. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008; 63: 163-181.
85. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645.
86. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD, et al. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 2006; 17: 313-316.
87. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.
88. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2727-2741.
89. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-137.
90. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009; 40: 147-155.
91. Bolognese M, Krege JH, Utian WH, et al. Effects of Arzoxifene on Bone Mineral Density and Endometrium in Postmenopausal Women with Normal or Low Bone Mass. J Clin Endocrinol Metab 2009; 94: 2284-2289.
92. de Paula FJ, Rosen CJ. Developing drugs to treat osteoporosis: lessons learned? Expert Opin Pharmacother 2010; 11(5): 867-869.
93. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in Postmenopausal Women with Osteoporosis. N Engl J Med 2010; 362: 686-696.
94. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23: 1923-1934.
95. de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22(2): 567-576.
96. Silverman S, Chines A, Zanchetta J, et al. Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study. J Bone Miner Res 2009; 24 (suppl 1)
97. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92: 1018-1024.
98. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009; 92: 1045-1052.
99. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 9: 804-820.
100. Tofteng CL, Bach-Mortensen P, Bojesen SE, Tybjaerg-Hansen A, Hyldstrup L, Nordestgaard BG. Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population. Pharmacogenet Genomics 2007; 17: 85-91.
101. Lee HJ, Kim SY, Koh JM, et al. Polymorphisms and haplotypes of integrin[alpha]1 (ITGA1) are associated with bone mineral density and fracture risk in postmenopausal Koreans. Bone 2007; 41: 979-986.
102. Murphy MG, Cerchio K, Stoch SA, et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005; 90: 2022-2028.
103. Wong BR, Besser D, Kim N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999; 4: 1041-1049.
104. Insogna KL, Sahni M, Grey AB, et al. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J Clin Invest 1997; 100: 2476-2485.
105. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6: 209-214.
106. Hannon RA, Clack G, Rimmer M, et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 2010; 25: 463-471.
107. Baselga J, Cervantes A, Martinelli E, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010; 16: 4876-4883.
108. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a-ápotential target in melanoma and other malignancies. Expert Opin Ther Targets 2007; 11: 91-100.
109. Verkman AS, Galietta LJV. Chloride channels as drug targets. Nat Rev Drug Discov 2009; 8: 153-171.
110. Piwon N, Günther W, Schwake M, Bösl MR, Jentsch TJ. ClC-5 Cl--channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 2000; 408: 369-373.
111. Cleiren E, Bénichou O, Van Hul E, et al. Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene the. Hum Mol Genet 2001;10:2861-2867.
112. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 2008; 42: 19-29.
113. Pettersson U, Albagha OM, Mirolo M, et al. Polymorphisms of the CLCN7 gene are associated with BMD in women. J Bone Miner Res 2005; 20: 1960-1967.
114. Kornak U, Ostertag A, Branger S, Benichou O, de Vernejoul MC. Polymorphisms in the CLCN7 gene modulate bone density in postmenopausal women and in patients with autosomal dominant osteopetrosis type II. J Clin Endocrinol Metab 2006; 91: 995-1000.
115. Chu K, Koller DL, Ichikawa S, et al. CLCN7 polymorphisms and bone mineral density in healthy premenopausal white women and in white men. Bone 2008; 43: 995-998.
116. Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004; 19: 1144-1153.
117. Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000; 25: 343-346.
118. Yuan FL, Li X, Lu WG, Li CW, Li JP, Wang Y. The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis. Mol Biol Rep 2010; 37: 3561-3566.
119. Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 2007; 22: 1640-1648.
120. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180-2189.
121. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Disassociation of bone resorption and formation by GLP-2: A 14-day study in healthy postmenopausal women. Bone 2007; 40: 723-729.
122. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009; 45: 833-842.